Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company’s common stock (the “Inducement Awards”) to two new employees pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). E...
Barnes & Noble College Launches Campus to Career, a NEW Offering to Help Students Build Real-World Skills to Enter the Workforce BASKING RIDGE, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Barnes & Noble College (BNC), a (NYSE: BNED) company and leading solutions provider for higher education, today announced the launch of Campus to Career — a new offering designed to equip college students with the tools, resources and insights they need to help transition from the classroom to the workplace. Campus to Career offers a curated collection of products available both in-store and online, along...
Barnes & Noble College Introduces Room Service – An Innovative Dorm Shopping and Delivery Service New service helps students and families skip move-in day stress with guided shopping and curated essentials delivered directly to residence halls BASKING RIDGE, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Barnes & Noble College (BNC), a (NYSE: BNED) company and leading solutions provider for higher education, today announced the launch of Room Service, a first-of-its-kind service designed to make shopping and moving-in easier and stress-free for college students and their families. Room Se...
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formula...
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s differentiated mechanism of action targets underlying pathology of NPC CELEBRATION, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Zevr...
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the , taking place September 2-6, 2025, in Kyoto, Japan. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick di...
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in the following September events: Cantor Global Healthcare Conference on Wednesday, Sept. 3, 2025, at 11:30 a.m. ET.H.C. Wainwright 27th Annual Global Investment Conference on Monday, Sept. 8, 2025, at 10:00 a.m. ...
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLO...
Barnes & Noble Education Receives NYSE Notice Regarding Delayed 10-K Filing BASKING RIDGE, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- On August 4, 2025, (NYSE: BNED) (the “Company”) received notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Annual Report on Form 10-K for the fiscal year ended May 3, 2025 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”). The Company determined that it would not be able to file the Form 10-K within the 15-day ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.